surpass 5 tirzepatide SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Tirzepatide Once Weekly in Children

I assess the appropriateness of the medication carefully and monitor closely when [these patients] are on a GLP-1 agonist. The caution is warranted, according to John Batsis, MD, an associate professor of medicine in the Division of Geriatric Medicine at the University of North Carolina at Chapel Hill School of Medicine, particularly because of the lack of clinical data on the specific impact of GLP-1 medications on older adults

Curran MWT, Morhart MJ, Olson JL, et al

When the comparison reaches the question of clinical proof, retinoids hold a significant advantage that honest analysis cannot overlook

10.1016/j.jneuroim.2013.04.013 68 FeitosaC